1. At a Glance – The ₹3,500 Crore Question Nobody Is Asking
Something unusual is happening at Indegene.
On the surface, this looks like a classic growth story:
- Revenue just crossed ₹3,500 crore for the first time
- Quarterly revenue crossed ₹1,000 crore — a psychological milestone
- Growth has re-accelerated to 23.6% YoY
- EBITDA margins are holding near 19–20%
Sounds like a textbook “high-quality digital services company,” right?
Now let’s disturb that comfort.
Despite all that growth, profit after tax declined YoY.
Margins shrank.
Depreciation exploded.
Working capital ballooned from ~39 days to 120 days.
And the most interesting part?
Management is celebrating cash flow strength while earnings quietly weaken underneath.
So what exactly is Indegene?
- A high-margin AI-enabled healthcare SaaS-like business?
- A disguised IT services company riding a temporary AI wave?
- Or a capital-light compounding machine… temporarily hit by acquisition noise?
Because the numbers are telling two different stories:
- Growth story (topline + AI narrative)
- Accounting reality (profit compression + amortization drag)
And when a company starts talking more about “adjusted EBITDA” than actual profit, you should at least raise one eyebrow.
Let’s sharpen the question:
If revenue is growing 23%, why isn’t profit growing?
That’s where this entire analysis begins.
2. Introduction – The AI Darling of Pharma… or Just Another Services Company?
Indegene sits at a very interesting intersection:
- Healthcare
- Technology
- Analytics
- Regulatory complexity
This is not your typical IT services firm.
And management makes that very clear.
They position themselves as:
“Revenue partners, not cost partners”
Translation:
They don’t just reduce costs like IT vendors.
They claim to drive revenue outcomes for pharma companies.
Now pause here.
This positioning is extremely powerful — if true.
Because:
- Cost vendors get squeezed during downturns
- Revenue partners grow when clients grow
And pharma is one of the few industries with:
- Long-term growth visibility
- Heavy regulation (high entry barriers)
- Increasing complexity (good for outsourcing)
Indegene claims to operate across the entire lifecycle:
- Drug development
- Clinical trials
- Regulatory submissions
- Marketing and commercialization
In short:
They are trying to become the operating system of pharma workflows.
Now add AI to the mix.
Management is aggressively pitching GenAI as:
- A productivity driver
- A scope expansion engine
- A competitive moat
Their logic is simple:
“AI will not reduce demand. It will multiply it.”
And to be fair, there is evidence:
- Content demand growing 3–4x
- Medical writing bottlenecks increasing
- Regulatory timelines shrinking
All of this creates outsourcing demand.
But here’s the uncomfortable reality:
Despite all this AI narrative:
- PAT declined YoY
- Margins compressed
- Acquisition-related costs are rising
So the real question is not:
“Is AI helping Indegene?”
The real question is:
“Who is capturing the value — Indegene or its clients?”
3. Business Model – WTF Do They Even Do?
Let’s simplify this without the jargon.
Imagine a pharma
